214 related articles for article (PubMed ID: 32648855)
1. Luspatercept to treat β-thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2020 Jul; 56(7):447-458. PubMed ID: 32648855
[TBL] [Abstract][Full Text] [Related]
2. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
Alashkar F; Klump H; Lange CP; Proske P; Schüssler M; Yamamoto R; Carpinteiro A; Berliner CA; Schlosser TW; Röth A; Reinhardt HC
Eur J Haematol; 2022 Dec; 109(6):664-671. PubMed ID: 36045599
[TBL] [Abstract][Full Text] [Related]
7. New partners for Luspatercept in β-thalassemia.
Vinchi F
Am J Hematol; 2024 Jul; 99(7):1217-1219. PubMed ID: 38752378
[No Abstract] [Full Text] [Related]
8. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
[TBL] [Abstract][Full Text] [Related]
10. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
11. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.
Darvishi-Khezri H; Karami H
Adv Ther; 2021 Apr; 38(4):1732-1745. PubMed ID: 33661441
[TBL] [Abstract][Full Text] [Related]
13. Acute liver injury after SARS-CoV-2 vaccination and luspatercept administration in a patient with β-thalassemia.
Leoni S; Bou-Fakhredin R; Granata F; Cassinerio E; Maggioni M; Fracanzani AL; Cappellini MD; Motta I
Ann Hematol; 2024 Mar; 103(3):1025-1026. PubMed ID: 38170241
[No Abstract] [Full Text] [Related]
14. Activin receptor ligand traps in chronic kidney disease.
Jelkmann W
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
[TBL] [Abstract][Full Text] [Related]
15. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years.
Musallam KM; Rivella S; Taher AT
Am J Hematol; 2021 Mar; 96(3):E57-E59. PubMed ID: 33219704
[No Abstract] [Full Text] [Related]
16. Unplanned pregnancy in women with beta-thalassaemia treated with luspatercept.
Zaccheddu E; Zappu A; Barella S; Clemente MG; Orecchia V; Pilia MP; Piras S; Pitturru C; Scarano M; Origa R
Br J Haematol; 2024 Jun; 204(6):2505-2507. PubMed ID: 38652468
[No Abstract] [Full Text] [Related]
17. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
[TBL] [Abstract][Full Text] [Related]
18. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience with luspatercept in transfusion-dependent β-thalassemia.
Roccotelli D; Grande D; Cicco G; Palma A; Longo MC; Albano F; Vitucci A; Musto P
Ann Hematol; 2023 Oct; 102(10):2965-2967. PubMed ID: 37498329
[No Abstract] [Full Text] [Related]
20. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
